I Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the ...

SOUTH SAN FRANCISCO, CA, USA I June 16, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of ...

ROCKVILLE, MD and CAMBRIDGE, MA, USA I June 16, 2025 I Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today ...

First patient dosed with Debiopharm’s first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients ...

MILAN, Italy I June 16, 2025 I AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and ...

Independent Data Monitoring Committee (DMC) has approved continuation of trial as planned with no modifications ...

New data show clinical safety and early efficacy of SANA, a first-in-class compound that targets creatine-dependent thermogenesis ...

TEL AVIV, Israel and SHANGHAI, China I June 16, 2025 I Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) ...

BELTSVILLE, MD, USA and SHANGHAI, China I June 16, 2025 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering ...

GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology ...

Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer's and other neurodegenerative diseases – ...